Gene-engineered CD34 + hematopoietic stem and progenitor cells (HSPCs) can be used to generate an HIV-1-resistant immune system. However, a certain threshold of transduced HSPCs might be required for transplantation into mice for creating an HIV-resistant immune system. Here, we combined CCR5 knockdown by a highly efficient miRNA lentivector with pre-transplantation selection of transduced HSPCs to obtain a rather pure population of gene engineered CD34+ cells. Low-level transduction of HSPCs and subsequent sorting by flow cytometry yielded >70% transduced cells. Mice transplanted with these cells 2 showed functional and persistent resistance to a CCR5-tropic HIV strain: viral load was significantly decreased over months, and human CD4 + T-cells were preserved. In one mouse, viral mutations, resulting presumably in a CXCR4-tropic strain, overcame HIV resistance. Our results suggest that HSPC-based
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Introduction
Combined anti-retroviral therapy (cART) changed the face of HIV medicine: patients have a lifeexpectancy close to uninfected people (1) . However, cART has major disadvantages, including adverse events, emergence of drug-resistant strains in patients with poor adherence, a need for life-long intake, psychological dependence, and cost. Thus, cART has not halted the pandemic (http://www.who.int/hiv/en/), and alternative therapies are needed to cure HIV.
Gene therapy has been widely discussed as a possible strategy to cure HIV and has been tested in phase I/II clinical trials. Autologous CD4 + T-cells (2, 3) or CD34 + cells (4, 5) were gene engineered to express various anti-HIV moieties, including a combination of three RNA-based anti-HIV moieties (tat/rev shRNA, TAR decoy, and CCR5 ribozyme) (4), a tat-vpr-specific anti-HIV ribozyme (5) , and a conditionally replicating lentiviral vector expressing long anti-sense to HIV (3) or were gene edited by zinc-finger nucleases for CCR5 knockout (2) . Gene engineering also generated HIV-specific CD4 + or CD8 + T-cells (6, 7) . Overall, the effects on HIV infection were modest, but importantly, gene engineering proved to be safe in humans.
The concept of engineering an HIV-resistant immune system received new impetus from the "Berlin patient," who was treated with hematopoietic stem cell transplantation for acute myeloid leukemia. He received bone marrow from a donor homozygous for the Δ32 CCR5 mutation, and thus, the progeny cells did not express CCR5. He was the first documented cure for HIV (8) and provided hope that eliminating CCR5 from the cell surface would be the "Holy Grail" for the cure of HIV. However, another HIVinfected patient suffering from anaplastic large cell lymphoma also received a stem cell transplant from a homozygous CCR5-null donor. Unfortunately, in that case, X4-tropic HIV strains emerged that necessitated the re-initiation of cART (9) .
In view of the modest success of phase I/II clinical trials and the data from stem cell transplantation, preclinical studies are needed to define the best anti-HIV moieties and the minimal number of gene engineered cells required to advance gene therapy in HIV. Humanized (hu) mice, which are generated by the transplantation of CD34 + cells, are of particular value in this context. Hu mice excel in their multilineage hematopoiesis (10) , are highly permissive to HIV (11) , and allow for the gene engineering of human CD34 + cells before transplantation (12) . Indeed, various anti-HIV moieties have been investigated in hu mice as gene therapy options, including cellular factors, boosting the anti-HIV-immune response, and the HIV genome itself (12) . These mice were used in extenso to investigate the effects of targeting CCR5 by shRNA (13) (14) (15) or ZNF (16) . All these studies reported a decrease in CCR5 expression in circulating and tissue leukocytes, which were not permissive to HIV ex vivo, but only the study by Holt et al. reported a significant decrease of HIV RNA copy number in vivo (16) . The other studies either did not analyse the effects on HIV infection in vivo (14) or demonstrated no effect on viral load (15 however the modest rate of gene engineering CD34+ cells (26) , the potential of off-target effects (27) (28) (29) and the lack of clinical experience represent substantial hurdles for wider use in vivo.
We recently reported a novel microRNA-based gene knock-down strategy with improved knock-down, relative to methods conventionally used (30 
Materials and Methods

Ethics statement
The procurement and use of CD34+ cells from human cord blood was approved by the Cantonal Ethical 
Lentiviral vector production and titration
Lentiviral vector stocks were generated using transient transfection of HEK 293T/17 cells with the selfinactivating vector, pCLX-R4-DEST-R2 encoding the microRNA to CCR5 (30), the psPAX2 plasmid encoding gag/pol, and the pCAG-VSVG envelope plasmid, as described (31) . Lentivector titration was performed using transduction of HT-1080 cells, followed by quantification of GFP-positive (or mCherry positive) cells 5 days after infection by flow cytometry as described (31) .
Generation of humanized mice
NOD.scid.IL2R −/− (NSG) mice were bred and maintained in individual ventilated cages and were fed autoclaved food and water. Mice with a human immune system (humanized (hu) mice) were generated as described (32 
Flow cytometry
The cells in whole blood were counted in a Beckman Cell Counter. 
HIV challenge ex vivo
Spleens of five hu mice transplanted with HSPCs gene engineered with the microRNA to CCR5 were dissociated through a nylon mesh, and red blood cells were lysed with ACK buffer for 3 minutes (LONZA). Cells were sorted (≥99% pure) with an ARIA sorter (BD Bioscience) into GFP-positive andnegative cells, and were subsequently activated for 24 hours with PHA (4 mg/ml) in RPMI culture medium supplemented with IL-2 (100 U/ml) and 10% fetal calf serum. Thereafter cells were infected with a TCID of 3. 
Statistical analyses
The statistical analyses were performed using GraphPad Prism 5.04 (GraphPad Software). Data were subjected to either unpaired t-tests or paired t-tests, as indicated in the figure legends. The P values obtained were considered significant when *P < 0.05. The statistical outlier analysis was performed using the GraphPad Outlier calculator with an alpha of 0.01 (http://graphpad.com/quickcalcs/Grubbs1.cfm).
Results
Transplanting CD34 + cells with partial CCR5 knock-down does not hinder HIV replication
We previously developed a highly efficient microRNA called "mirGE" that allows efficient knock-down by single-copy transduction (30) . Here we explored the potential of a mirGE lentivector targeting CCR5 to produce an HIV-resistant immune system in hu mice. The construct consists of a triple hairpin, and the vector cassette contains GFP driven by the same promoter as the miRNA that allows transduced cells to be identified directly. To minimize possible cellular perturbations from multiple vector inserts, we established a protocol that gave us a transduction rate of 20-30%. This transduction rate was based on previous work and should correlate with single-copy integration (36) . of various cohorts of mice. Blood: mean ± sem .; *P = 0.0237, *'P = 0.0121, **P = 0.0035, ***P = 0.0007, ****P = 0.0001.
Spleen: mean ± sem.; *P = 0.041, ***P = 0.0003. P values determined by two-tailed unpaired t-test. (e) HIV replication is inhibited ex vivo in GFP-positive sorted splenocytes from R5 knock-down mice. Splenocytes were isolated from R5 knock-down mice 20 weeks after CD34+ cell injection. Splenocytes were sorted into GFP-positive (n=5) and GFP-negative (n=5) fractions at 99% purity and challenged with R5 tropic HIV (YU-2). The amount of HIV production in the culture supernatant was monitored by HIV p24 ELISA. Viral loads were normalized to the peak viral load in each condition (mean ± sem).
h). The CD4+ cell population, however, remained the same over the observation period of 92 days (cohort 1), or showed a CD4+ T-cell loss only at day 134 days (cohort 2) (Fig. 1b) . We explain this increase in GFP+ HIV-resistant CD4+ cells as the result of preferential expansion at the cost of untransduced CD4+
T-cells, while the lymphoid system tries to keep the lymphoid T-cell number constant. However, HIV replication was similar in R5 knock-down mice and control-transduced mice over the observation period at 92 and 134 days (Fig. 1c) . Analysis of absolute numbers of CD4 + T-cells (cohort 2) indicated that the control-transduced mice lost CD4 + T-cells; whereas, they were more or less maintained in the R5 knockdown mice (data not shown).
In the R5 knock-down mice, CCR5 was down-regulated in the GFP-positive CD4 + T-cells, but CCR5 was detected on the GFP-negative CD4 + T-cells in blood and spleen (Fig. 1d ). In the control-transduced mice, Analysis of the peripheral blood in six of the FACS-sorted R5 knock-down animals showed a single GFPpositive peak for human CD45 + and CD4 + T-cells, suggesting that only transduced CD34 + cells engrafted in these mice (Fig. 2) ; the level of GFP-positive cells was a major criterion for successful gene engineering and engraftment. Mice transplanted with the GFP-negative fraction were called "FACS-sorted negative mice." They developed CD4 + and CD8 + T-cell populations with no GFP expression (Fig. 2) . In contrast, the control-transduced mice had two distinct GFP-negative and -positive populations for CD45 + and CD4 + T-cells (Fig. 2) . A summary of mice used in this study is indicated in (Table 1) . Mice with less than 5% human engraftment in the peripheral blood before HIV infection were excluded. 
T-cells (>20%)
Untransduced n/a 15 11 n/a n/a n/a FACS GFP-negative n/a 26 15 n/a n/a n/a
Transplanting purified CCR5 knock-down CD34 + cells dramatically lowered viral load and protected HIV target cells in vivo
The FACS-sorted R5 knock-down mice had markedly lower viral loads than the FACS-sorted negative mice over 28 weeks (Fig. 3a) . Peak viremia for the FACS-sorted R5 knock-down mice was on average 4.2x10 3 copies/ml, and FACS-sorted negative mice had 3.5x10 5 copies/ml. Viral loads for the untransduced, control-transduced, R5 knock-down, and FACS-sorted negative mice were similar. The FACS-sorted R5 knock-down mice had lower viral loads than all cohorts.
CD4 + T-cells (percentage of total CD3
+ T-cells) from the FACS-sorted negative mice declined steadily upon infection (day 0: 55%; day 134: 20%) (Fig. 3b) . In contrast, the FACS-sorted R5 knock-down mice showed a steady increase in CD4 + T-cells (day 0: 33%; day 196: 65%). Furthermore, the absolute numbers of CD4 + T-cells increased for the FACS-sorted R5 knock-down mice but decreased for the FACS-sorted negative mice (data not shown).
At euthanasia, for the FACS-sorted R5 knock-down mice, 70% of CD4 + T-cells in the blood and 83% of CD4 + T-cells in the spleen were GFP-positive ( Fig. 3c-d ). In the control-transduced and R5 knock-down groups, this was on average 20% and 18% in the blood and 21% and 20% in the spleen, respectively (Fig.   3c,d) . Similarly, the CD4 + /CD8 + T-cell ratios in the blood and spleen (end/pre-infection) were very low in the various groups except for the FACS-sorted R5 knock-down group (Fig. 3e,f) . Absolute numbers of GFP-positive CD4 + T-cells expanded significantly upon HIV challenge in the FACS-sorted R5 KD mice ( Fig. 3i) , and CCR5 expression was down-regulated in the blood and spleen of the FACS-sorted R5 knock-down mice (Fig. 1d) .
In summary, transplantation of GFP-positive sorted CD34 + cells produced mice with high levels of geneengineered CCR5 knock-down CD4 + T-cells in vivo. This resulted in long-term inhibition of HIV replication in vivo and preservation of HIV target cells in the blood and spleen.
Outlier analysis and follow-up of mice that did not meet acceptance criteria
The FACS-sorted R5 knock-down mice typically controlled the virus long-term (titers < 10 4 copies/ml) while maintaining a high level of GFP-positive CD4 + T-cells in the blood (Fig. 4a) . In contrast, a single FACS-sorted R5 knock-down mouse (#954) showed an unexpected decline in GFP-positive CD4 + T-cells with high HIV copy numbers, >10 5 copies/ml on days 57 and 92 (Fig. 4a) . We performed an outlier analysis (see methods section), and at four different times, viral loads detected in animal #954 were statistical outliers (Fig. 4a) . Based on this, animal #954 was not included in the mean values and was analyzed separately (see below). At termination, this mouse had much lower splenic engraftment of total human splenocytes with 31% human cells compared to the FACS-sorted R5 knock-down mice which had 54% (mean ± sem: 11%). GFP-positive CD4 + T-cells were barely detected in the spleen of mouse #954 (6%), while the FACS-sorted R5 knock-down mice had, on average, 83% (mean sem ± 2%) GFP-positive CD4 + T-cells in the spleen (Fig. 3d) .
The inclusion criterion we defined as successful reconstitution for FACS-sorted R5 knock-down mice was 70% GFP + CD4 + T-cells in the peripheral blood before infection. Four mice did not meet these criteria despite being transplanted with GFP-positive sorted CD34 + cells (Fig. 4b) . Mouse #1113 had no protection against HIV and had a limited expansion of GFP-positive CD4 + T-cells (23% on day 0 to 43% on day 137). Mice #958 and #1115 had massive expansions of GFP-positive cells reaching close to 100%
of the total CD4 + T-cell population which went in parallel with a decrease in the viral load (Fig. 4b) . For mouse #1608, the dynamics of GFP-positive CD4 + T-cell recovery and viral load were slower, and GFPpositive CD4 + T-cell recovery on day 134 was less extensive (Fig. 4b) . These three mice (#958, #1115, 
Preserved engraftment and preferential expansion of central memory T-cells in FACS-sorted R5 knock-down mice upon HIV infection
Engraftment as reflected in peripheral blood decreased in all control cohorts but increased in the FACSsorted R5 knock-down mice (Fig. 5a ). This effect on total engraftment was even more impressive in the spleen. FACS-sorted R5 knock-down mice had 10 times more human cells than control cohorts (Fig. 5b) .
We evaluated the CD4 + and CD8 + effector (CD45RA pos ; CCR7 (Fig. 5d,f) . We observed no differences between the cohorts for effector and effector memory cells (data not shown). Notably, however, there was a trend towards a decrease in naive CD4 + and CD8 + T-cells in all cohorts (data not shown). Evidence of shift from R5 to X4 tropic strain in one mouse
As described above (Fig. 4) , FACS-sorted R5 knock-down mice had a low viral load and maintained high levels of CCR5 knock-down CD4 + T-cells. Mouse #954 was clearly an outlier: it had high viral titers and lost GFP-positive CD4 + T-cells (Fig 6a) . We hypothesized that this mouse might have had a tropism shift of the virus from R5 to X4. We performed HIV population sequencing (from plasma) on days 57 and 196.
As a control, we analyzed mouse #958 (Fig. 6b) . Sequencing revealed no mutations in mouse #958.
Mouse #954 had mutations in the V3 loop of the HIV envelope sequence (Fig. 6c) , resulting in amino acid substitutions to basic amino acids as indicated (Fig. 6d) . Substitutions in the V3 loop to basic amino acids have been reported to result in a switch from R5 to X4 tropism (38) .
Discussion
Here we investigated a lentiviral vector-based, CCR5-targeting miRNA as a tool for engineering an HIVresistant human immune system. We show that i) the miRNA-based vector was very efficient in down- and to affect cellular homeostasis than the widely used shRNAs (42, 43) . However, miRNAs are thought to have a lower capacity to down-regulate target genes than shRNAs. Here we used a miRNA we developed with optimized features that efficiently knock-down target genes upon single-copy vector transduction (30) . Ex vivo sorted cells were indeed resistant to a challenge with CCR5-tropic strains.
However, bulk transplantation of transduced CD34+ cells into mice resulted in a human lymphoid system that replicated HIV similar to untransduced hu mice but preserved CD4+ T-cell counts. Similar data have been reported (15) .
We hypothesized that the majority of HSPCs needs to be gene engineered to see an effect on the HIV load; otherwise, the HIV permissive CD4+ T-cells that originated from the untransduced CD34+ cells Whether additional factors contribute to HIV lowering effects remain unknown.
White blood cell counts from HIV-infected mice generated with FACS sorted R5 KD cells showed an expansion of central memory CD4+ and CD8+ T-cells, while all other groups showed a progressive loss of these CD4+ memory T-cells and no change in CD8+ T-cells. This pattern was also evident when looking at the splenocytes. These memory CD8+ T-cells might have contributed to the control of HIV.
There was a decrease in the frequency of naive CD4+ and CD8+ T-cells in the peripheral blood in both FACS-sorted negative and FACS-sorted R5 KD mice, whereas in the spleen, the naive CD4+ and CD8+
T-cells in the FACS-sorted R5 KD mice tended to be higher (data not shown). The expansion of central memory T-cells is reminiscent of the immune reconstitution seen in HIV-infected patients on ART (48) HIV is known for its high mutational rate. In this respect, we observed one mouse (#954) with an escape mutation. Despite high levels (day 0) of engraftment of CCR5 knock-down cells, this mouse had a high viral load and a complete loss of circulating CD4 + T-cells. Population sequencing of the V3 loop indicated a likely shift to X4 tropism which might explain the uncontrolled infection. The mutations were detectable in the blood only at relatively late time points. This might be due to an initial compartmentalized replication of the X4-tropic strains in the thymus. We previously showed that X4-HIV NL4-3 severely depleted the thymus, whereas YU-2 only had minor effects (49) . However, we do not know whether the potential emergence was due to the CCR5 knock-down or was just a coincidence. Indeed, emergence of CXCR4-tropic strains may occur without any immune or drug pressure in hu mice infected with CCR5-tropic strains (50) . In any case, CCR5 knock-down should be done in concert with another strategy to constrain HIV (i.e., including another anti-HIV moiety, combining with efficient antiretrovirals, or boosting the immune response in parallel to transplantation). Indeed, the solidness of successful gene engineering by the expression of more than one antiviral moiety may prevent HIV evolution (51) . Gene engineering could be combined with conventional ART: combining two treatment modalities was efficient in cell lines (52) , as induction therapy (53) 
